Spectral AI (MDAI) Q4 2024 earnings summary

Executive summary

• Achieved $29.6 million in FY 2024 R&D revenue, up 63.5% year-over-year, driven by BARDA PBS contract and positive top-line results from a major burn validation study where DeepView outperformed clinicians in sensitivity, Dice score, and specificity.

• Expanded global presence with DeepView deployments in Australia and the U.K., gathering clinical feedback to support FDA submission and commercialization.

• Launched Spectral IP subsidiary to monetize intellectual property, with plans to spin off as a separate public company by Q2 2025.

• Secured multi-year, non-dilutive BARDA PBS contract valued up to $150 million, supporting development and procurement.

• Strengthened financial position with $11.2 million raised in Q1 2025 through debt and equity financing.

Financial highlights

• Q4 2024 R&D revenue was $7.6 million, up from $5.3 million in Q4 2023; full year 2024 R&D revenue reached $29.6 million, a 63.5% increase from $18.1 million in 2023.

• Gross margin for 2024 improved to 44.9% from 43.6% in 2023; Q4 2024 gross margin was 44% (down from 46.1% in Q4 2023).

• Q4 2024 net loss was $(7.7) million ($(0.41)/share); FY 2024 net loss was $(15.3) million ($(0.85)/share), including $4.6 million warrant liability charges and $2.9 million borrowing expenses.

• General and administrative expenses decreased to $19.9 million in 2024 from $20.9 million in 2023.

• Cash and cash equivalents stood at $5.2 million at year-end, with an additional $11.2 million raised in Q1 2025.

Outlook and guidance

• Forecasting $21.5 million in revenue for fiscal year 2025, excluding potential commercial sales from the U.K. and Australia.

• Anticipates FDA submission for DeepView by end of Q2 2025, targeting de novo classification in 2026.

• Expects first commercial product revenue in H2 2025 and commercial revenue across four DeepView platforms within three years.

• Expects DeepView Snapshot M to be ready for military deployment in 2027, with ongoing development milestones in 2025.